AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma

Shots:

• AstraZeneca to receive $350M up front, up to $40M as commercial milestones b/w 2020 to 2022. Atnahs to get global commercial rights (Ex- US, India and Japan) of Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone FD combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide FD combination)
• AstraZeneca will retain rights in Japan and will continue to manufacture & supply the therapies during the transaction period. The divestiture is expected to be completed in Q1’20
• Inderal and Tenormin are beta-blockers, used to treat angina hypertension and arrhythmias. Zestril is an ACE inhibitor indicated to treat hypertension, CHF, diabetic-related conditions and hypertensive renal disease

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: StraitTimes